Tenax Therapeutics, Inc. has announced a temporary pause in enrollment for its LEVEL-2 clinical trial, a strategic move influenced by findings from its recently completed Phase 3 LEVEL trial of TNX-103, aimed at treating pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF). This decision reflects the company's commitment to enhancing patient selection criteria to maximize the trial's effectiveness and align with regulatory expectations.
The LEVEL-2 trial is crucial for Tenax as it seeks to develop TNX-103, a treatment that has shown potential in improving exercise tolerance among patients. The company plans to amend the enrollment criteria based on insights gained from the LEVEL trial, which will help identify patients most likely to benefit from the treatment. Tenax has also requested a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss the overall development strategy for levosimendan, the active ingredient in TNX-103.
Background
Tenax Therapeutics, Inc., incorporated in Delaware, operates in the pharmaceutical preparations sector (SIC 2834). The company is publicly traded on the Nasdaq under the ticker TENX. Its focus is on developing innovative therapies for patients with serious cardiovascular and pulmonary conditions. Recent filings include a series of updates on its clinical trials and corporate strategies, with the latest 8-K filed on October 8, 2026.
What the Filing Says
The filing states, "As previously announced, Tenax Therapeutics, Inc. is enriching its LEVEL-2 clinical trial based on key learnings from its recently completed Phase 3 LEVEL trial of TNX-103 in PH-HFpEF." It further explains that the company intends to amend LEVEL-2 enrollment criteria to maximize patient enrollment and improve trial outcomes.
Impact
This update may significantly affect patients enrolled in the LEVEL-2 trial, as the pause allows for a more targeted approach to enrollment. It may also impact investors and stakeholders in the pharmaceutical industry, particularly those focused on treatments for pulmonary hypertension. The decision underscores the importance of data-driven strategies in clinical trial design, which could influence future developments in the sector.
What's Next
The filing does not specify what happens next beyond the amendment of the enrollment criteria and the request for a meeting with the FDA. Further updates are expected as the company refines its approach and resumes enrollment in the LEVEL-2 trial.